Credit Suisse lowers cspc pharma's target price to HK$12, reiterating an 'outperform' rating.
[Brokerage Focus] Zhongtai International cuts the target price of CSPC Pharma (01093) by 15%, indicating that its performance for the first three quarters will be lower than market expectations.
CSPC Group (1093HK): The proprietary medicine sector slowed significantly in the third quarter, putting pressure on short-term performance
Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$8.46 From HK$9.29, Keeps at Buy
[Brokerage Focus] Nomura cuts target price of CSPC Pharma (01093) by 8.9%, expecting a 4.3% year-on-year decline in third-quarter profit.
Bocom Intl: rates the Mainland pharmaceutical industry as "leading", focusing on innovative and consumer-driven targets.
CICC: Maintains cspc pharma (01093) 'Outperform' rating with a target price of HKD 8.4.
CSPC Group (1093.HK): LP (A) inhibitors achieve accelerated internationalization of external authorization
Goldman Sachs: Buy rating on cspc pharma, the trade with astrazeneca is an important step in global expansion.
Goldman Sachs: Buy rating on CSPC Pharma (01093) with a target price of HK$10.03.
[Brokerage Focus] First Shanghai recommends buying CSPC Pharma (01093) and expects its new products to be approved successively, with the pharmaceutical sector poised to resume high growth.
CSPC Group (1093.HK): Short-term pressure growth slows due to collection, new products are being approved one after another, and the future can be expected
Lyon: Reiterate cspc pharma (01093) with an outperform rating, target price of 9.1 Hong Kong dollars.
Major Rating | Lyon: Reaffirms the "outperform the market" rating for Shiyao, and continues to increase shareholder returns.
CSPC Group (1093.HK): Pharmaceutical holdings increase performance under short-term pressure, and many new drugs have been approved one after another
CSPC PHARMACEUTICAL(1093.HK):LEGACY PRODUCTS FACED PRICING PRESSURES
CSPC Group (01093.HK): Steady growth in the neurological field, the tumor sector is under pressure and innovation can be expected
Hong Kong stocks fluctuated | CSPC Pharma fell more than 14%, hitting a new low in the stage, and its mid-term performance was lower than expected, leading to Goldman Sachs cutting its target price.
Review of the 2024 Semi-Annual Report of CSPC Pharmaceutical Group (1093.HK): Performance is slightly lower, and innovation and transformation can be expected
Bank of China International Downgrades CSPC Pharmaceutical to Hold From Buy; Price Target Is HK$6.50
No Data
No Data